At The Body Clinic, we are always at the forefront of innovations in the world of Medical Weight Loss. One of the newest developments currently receiving a lot of attention is Retatrutide. This medication, developed by Eli Lilly, is expected to be the next step in addressing and treating overweight and obesity. However, Retatrutide has not yet been approved by European and Dutch authorities and is therefore not available as a treatment.
What is retatrutide?
Retatrutide is a once-weekly injectable drug that affects multiple hormone receptors in the body. Preliminary research results therefore show promising effects on weight loss in overweight or obese people. The drug is a so-called tri-agonist, which means it stimulates three different hormone receptors at the same time:
- GLP-1: Lowers appetite and improves blood sugar levels;
- GIP: Stimulates insulin release and may help reduce fat mass;
- Glucagon: Increases energy consumption and promotes fat metabolism.
Eli Lilly
Eli Lilly is a leading pharmaceutical company founded in 1876 in the United States. They focus on developing innovative medicines for global health problems. They are known for their focus on scientific research, which has led them to now find treatments for diabetes, oncology, immunology and obesity management.
The obesity pandemic
Retatrutide is being developed in response to the obesity pandemic. Obesity is a complex chronic disease that often involves other ailments such as type II diabetes, high blood pressure and cardiovascular disease. If approved, retatrutide could potentially help manage overweight and obesity.
The future of retatrutide
Retatrutide is in the final stages of clinical trials and thus is not yet available. The Body Clinic is closely monitoring the progress of retatrutide and if the drug is approved, we will be able to offer more information about it.
Do you have a BMI of ≥27 with a weight-related condition or a BMI of ≥30 and are curious about what options are already available in the field of Medical Weight Loss? Then schedule a no-obligation intake with one of our physicians.
